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Abstract
Purpose The management of cervical cancer in preg-
nancy persists to be challenging. Therefore, identification
of factors that influence the choice of therapeutic man-
agement is pivotal for an adequate patient counseling.
Methods We present a literature review of 26 studies
reporting 121 pregnancies affected by cervical cancer.
Additionally, we add a retrospective case series of five
patients with pregnancy-associated cervical cancer diag-
nosed and treated in our clinic between 2006 and 2013.
Results The literature review revealed that the therapeutic
management during pregnancy varies according to the
gestational age at diagnosis, while in the postpartum period
no influence on the treatment choice could be detected.
Also in our case series the choice of oncologic therapy was
influenced by the gestational age, the wish to continue the
pregnancy and the risks of delaying definitive treatment.
Conclusions There are no standardized procedures con-
cerning the treatment of cervical cancer in pregnancy.
Therefore, in consultation with the patient and a multidis-
ciplinary team, an adequate individualized treatment plan
should be determined.
Keywords Cervical cancer  Pregnancy  Treatment 
Chemotherapy  Review  Case series
Introduction
Cervical cancer (CC), comprising both squamous and
glandular differentiation, is not only the fourth most fre-
quent malignancy but also the fourth leading cause of
cancer-related death in women worldwide. Among the
malignant tumors of the cervix, squamous cell carcinoma
(SCC) is the most common subtype and therefore charac-
terizes the clinical and epidemiological picture of the dis-
ease. Although the tumor is virtually preventable by human
papillomavirus (HPV) vaccination and effective screening
strategies, its peak occurrence coincides with the prime
reproductive years in non-compliant populations [1].
Accordingly, CC is one of the three most common preg-
nancy-associated cancer types with a crude incidence rate
of 4 per 100,000 pregnancies [2]. Different data suggest
that a diagnosis in pregnancy does not affect survival rates
negatively [3]. However, these observations should be
handled with care due to limited literature. The treatment
of CC in pregnancy is complex. It has to take into con-
sideration the optimal oncologic therapy as well as the
preservation of the health of the fetus. Treatment options
include conservative and surgical approaches based on
tumor size, lymph node involvement, gestational age (GA)
and the patient’s wish to continue the pregnancy [4]. To
Electronic supplementary material The online version of this
article (doi:10.1007/s00404-015-3980-y) contains supplementary
material, which is available to authorized users.
& Kirsten Ku¨bler
Kirsten.Kuebler@ukb.uni-bonn.de
1 Department of Gynecology, Center for Integrated Oncology,
University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn,
Germany
2 Department of Obstetrics and Prenatal Medicine, University
of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany
3 Institute of Pathology, Center for Integrated Oncology,
University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn,
Germany
4 Department of Radiology, Center for Integrated Oncology,
University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn,
Germany
123
Arch Gynecol Obstet (2016) 293:931–939
DOI 10.1007/s00404-015-3980-y
help provide a basis for treatment decisions, we here report
our clinical management of five women diagnosed and
treated with SCC during pregnancy. Additionally, we
present a literature review focused on treatment options of
gestational CC. We hypothesized that the GA at diagnosis
might influence the choice of treatment and aimed to
evaluate whether this might affect maternal outcome.
Materials and methods
Patients
We retrospectively reviewed the medical files of 84 preg-
nant women out of a total of approximately 2800 patients
who presented at the outpatient department for genital
dysplasia of Bonn University between 2006 and 2013.
Patients were retrieved from the pathological database
(PathoPro software, Institute for Medical Software, Saar-
bru¨cken, Germany) using the following search terms:
‘pregnancy’, ‘weeks of gestation’, ‘cervical dysplasia’ and
‘abnormal Pap smear’. Out of the cohort, five (5.95 %)
patients with SCC were identified and included in this case
series. Clinical information was gained from medical
records; developmental charts were used to assess health
outcome of newborns; follow-up data were updated until
October 2015. In all women, colposcopy was performed
using the photo and video colposcope 3MV (Leisegang,
Berlin, Germany); image processing was carried out using
the 3MV-Videology Viewer software 3.8.5.6 (Leisegang);
application of 3 % acetic acid allowed the identification of
cervical epithelial changes. Additionally, in all patients,
colposcopy-directed biopsies of suspicious lesions were
undertaken. Pap tests were evaluated according to the
Munich nomenclature II; World Health Organization
(WHO) criteria were used for histopathological diagnosis;
tumor grade was determined based on the modified Bro-
ders’ classification [5]; tumors were staged clinically
according to the International Federation of Gynecology
and Obstetrics (FIGO) system [6]; the lymph node status
was recorded separately.
Literature search
A systematic computerized search was performed using
PubMed and Web of Science (1995-2014) with the lan-
guage being restricted to English. The PubMed query was
conducted by combining the following MeSH (Medical
Subject Headings) terms: ‘pregnancy complications/neo-
plastic/therapy’, ‘uterine cervical neoplasms’ and ‘carci-
noma/squamous cell’; the MeSH keyword ‘trachelectomy’
was excluded. A similar strategy was applied to the Web of
Science database using the following query: Title
(TI) = (cervical cancer) AND TI = (pregnancy) AND
Research Area (SU) = (Oncology) AND TS = (therapy)
AND TS = (squamous) NOT Topic (TS) = (trachelec-
tomy). Abstracts were explored for relevant information;
full-text articles were used for further details. Authors were
contacted if the complete manuscript could not be retrieved
otherwise. Publications to be reviewed were selected by
TH and KK. Case reports and retrospective trials were
included; unpublished data were not accepted.
Thirty-seven studies met inclusion criteria. Three pub-
lications were excluded since they provided a review only
[7–9]; two publications were excluded since they analyzed
preneoplastic lesions [10, 11]; three publications were
excluded since they did not provide original data to each
patient [12–14]; two publications were excluded since we
were unable to retrieve the whole publication [15, 16]; one
publication was excluded since a successful pregnancy
after the treatment of CC was reported [17]; 26 studies
reporting 121 pregnancies [18–43] were used for the sys-
tematic review. The following data points were collected:
baseline characteristics (age at diagnosis, GA at diagnosis),
tumor characteristics (FIGO stage, histopathology), therapy
(during pregnancy, in the postpartum period), obstetric
characteristics (obstetric history, mode and GA of delivery,
neonatal outcome) and maternal outcome. Our aim was to
identify typical pattern and trends according to the GA at
diagnosis. Therefore, patients were divided by their time
point of tumor detection in early (\20 weeks (wks) GA)
and late-diagnosed (C20 wks GA) disease.
Statistical analysis
The F test was used to analyze the assumption of equal
variances; the unpaired two-tailed Student’s t test was used
to compare differences in the following groups: age at
diagnosis, GA at delivery and follow-up. For categorical
variables the Chi-square test was used to investigate sta-
tistical significance of differences: FIGO stage,
histopathology, therapy during pregnancy, therapy in the
postpartum period, mode of delivery and status of maternal
outcome. Additionally, Yates correction was performed.




Five cases of SCC in pregnancy were identified during the
study period. Median age at diagnosis was 32 years (range
30–37; Table 1). Risk factors included tobacco use and
high-risk HPV positivity. Three patients did not participate
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in the screening program; two women had abnormal Pap
smear results before getting pregnant. All patients were
referred to a colposcopic examination during pregnancy.
Diagnosis of SCC was made by biopsy in four pregnant
women; in one patient, cervical intraepithelial neoplasia
(CIN) III was detected in gravidity. However, in the
postpartum period, the conization tissue showed malignant
cells suggesting progression of the disease. Four biopsies
were performed in the second and one in the third trimenon
for the diagnosis of cancer. All Pap smears were without
evidence of malignancy. All patients of our case series
were diagnosed with early staged SCC (Table 2). Poor
prognostic factors included the presence of lymph node
metastasis in one patient, lymphovascular invasion (LVI)
in two and low differentiation in three women.
Of all patients diagnosed with SCC in the second tri-
menon, one woman decided to terminate pregnancy (case
4). Radical hysterectomy with the fetus in situ and bilateral
pelvic lymph node dissection was performed at the GA of
19 wks. Another woman was treated by conization at
21 wks of gestation (case 1). In this case, early staged SCC
with negative margins for invasive disease was diagnosed.
Pregnancy was prolonged, regular colposcopic controls
were undertaken, and a cesarean delivery (CD) plus hys-
terectomy was performed at 35 wks of gestation. The final
pathologic examination showed residual CIN but no inva-
sive disease. The tumor of the third patient diagnosed in the
second trimenon (20 wks GA) was 3 cm in diameter and
exhibited LVI (case 5) [44]. Since this patient wished to
continue her pregnancy, four cycles of neoadjuvant
chemotherapy with cisplatin were administered. Clinical
and colposcopic follow-ups were scheduled every 3 weeks
confirming stable disease (Fig. 1a). An abdominal mag-
netic resonance imaging (MRI) scan at 20 wks of gestation
was performed using a 1.5-T system (Intera, Philips
Medical Systems, Best, Netherlands) to rule out lymph
node involvement and advanced disease (Fig. 1b). Staging
laparoscopy was refused by the patient. The fetal well-
being was monitored regularly with ultrasonography and
Doppler scan and showed no signs of intrauterine growth
restriction. The patient tolerated chemotherapy well with-
out any significant side effects. After reaching fetal pul-
monary maturity, CD and radical hysterectomy with pelvic
lymphadenectomy were performed at 35 wks of gestation.
To assess the effect of chemotherapy on cell proliferation,
2–3 lm formalin-fixed paraffin-embedded tissue speci-
mens were stained with the mouse antihuman Ki-67 IgG1
monoclonal antibody (clone MIB-1, dilution 1:500; Dako,
Hamburg, Germany) using an automated staining system
(Medac 480 S Autostainer; Medac, Wedel, Germany),
HRP-conjugated goat anti-mouse IgG and the DAB system
(Medac). The pathologic examination revealed a Ki-67
activity of 36.47 % after neoadjuvant chemotherapy com-
pared to a proliferation index of 32.22 % at initial diag-
nosis suggesting stable disease (Fig. 1c). In the postpartum
period, the patient received adjuvant treatment consisting
of cisplatin-based radiochemotherapy.
In one patient, SCC was diagnosed in the early third
trimenon (case 2). Due to a history of abnormal Pap smears
over the past 5 years, she was referred to our colposcopic
unit in early pregnancy. Cytologic results were normal, and
accordingly, no colposcopy-directed biopsy was taken.
However, the colposcopy in 32 wks of gestation showed a
suspect area. Consequently, a biopsy was done revealing
high-grade CIN with focal micro-invasive SCC. CD was
performed at 36 wks of gestation; a conization was
undertaken in the postpartum period.
In one case, SCC was diagnosed in the postpartum
period (case 3). The patient was referred to our clinic
8 wks after delivery, and a conization was performed
diagnosing invasive disease. Radical hysterectomy with
pelvic lymph node dissection was undertaken. Addition-
ally, the patient received adjuvant treatment consisting of
cisplatin-based radiochemotherapy and brachytherapy.

























1 37 Yes HRa No ND IVb/ND/ND 18 SCC NED 106.51
2 34 No 16 Yes IIID II/II/ND 32 SCC NED 52.20
3 30 No HRa No ND IIID/IIID/IVa 26 CIN IIIb NED 44.84
4 32 Yes HRa No ND IVa/ND/ND 16 SCC NED 78.24
5 32 Yes HRa Yes III III/IVa/ND 20 SCC NED 25.90
GA gestational age, CIN cervical intraepithelial neoplasia, HPV human papillomavirus, HR high risk, mths months, NED no evidence of disease,
ND not determined, SCC squamous cell carcinoma, wks weeks, yrs years
a HPV types not specified
b Diagnosis of SCC was made by conization in the postpartum period
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20 wks GA 28 wks GA 32 wks GA24 wks GA
20 wks GA pre-chemotherapy post-chemotherapy
(a)
(b) (c)
Fig. 1 An example of the individual management of cervical cancer
FIGO stage IB1 in pregnancy (case 5, after [44]). a Colposcopy in
pregnancy was performed at initial diagnosis and subsequently during
neoadjuvant chemotherapy to monitor the response to treatment;
acetic acid was used for the visualization of cervical changes. Signs of
invasive disease included atypical vessels and ulceration (arrow). b A
pelvic MRI scan was performed at 20 wks GA and ruled out lymph
node involvement; the sagittal T2-weighted image identifies the
tumor by an increase in size and signal intensity (arrow). c Repre-
sentative images of Ki-67 expression in non-treated and treated SCC
visualized by immunohistochemistry (brown, arrow); hematoxylin
(blue) was used for nuclear staining (bright field image, 9100
magnification)
Table 2 Tumor characteristics
Case FIGO
Stage














1 IA1 ND Absent Absent 3 R0 Absent Conization (21), CD and
hysterectomy (35)
Absent
2 IA1 ND Absent Absent 2 R0 Absent CD (36), conization in the
postpartum period
Absent








4 IB1 Absent Absent Absent 3 R0 Absent Radical hysterectomy with
fetus in situ and pelvic
lymphadenectomy (19)
Absent









CD cesarean delivery, BVI blood vessel invasion, GA gestational age, LVI lymphovascular invasion, ND not determined, R0 complete resection
with microscopically negative margins, wks weeks
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With regard to the obstetrical history, the median ges-
tational age at delivery was 35.5 wks (range 35–40;
Table 3). All children were born with average birth weights
for their GA. No significant complications at birth and
neonatal course were noted. No long-term complications
were detected. In particular, the child whose mother
received platinum-based chemotherapy during pregnancy
showed a normal development. As of today, all patients
(Table 1) and their children (Table 3) undergo regular
checkups and are healthy and alive.
Review of the literature
Details for each case of the literature review are given in
Supplementary Table S1. Tumors were classified according
to their GA at detection in early and late-diagnosed disease,
and variables were compared (Table 4). No difference was
found between groups regarding patient and tumor char-
acteristics as well as maternal outcome. We identified a
significant discrepancy in the oncological management
during pregnancy but not after delivery between early- and
late-diagnosed tumors. Accordingly, the GA and the mode
of delivery differed in both groups.
Discussion
Although its incidence rate has been declining in the last
years, CC is one of the most frequently diagnosed malig-
nancies in pregnancy. Due to an increase in women
choosing to become pregnant later in their lives, even a
further rise of gestational CC is plausible [2]. Literature on
the clinical management of CC in pregnancy is scarce.
Therefore, we retrospectively analyzed pregnancy-associ-
ated CC cases in our clinic and performed a literature
review that focused on treatment approaches.
We found therapeutic modalities in pregnancy still to be
limited consisting mainly of conization and chemotherapy.
Alternatively, tumors can either be followed up or preg-
nancy can be interrupted for definitive therapy according
to guidelines [45]. Treatment decisions in pregnancy
depended on the GA at first diagnosis. Accordingly,
women obtained interruptions until 20 wks after concep-
tion more often as women who are more than 20-wk
pregnant. In the latter case, the concept of ‘watchful
waiting’ appeared to be typical. According to these results,
also the mode and the GA at delivery correlated with the
time point of first diagnosis in pregnancy. However, dif-
ferent treatment approaches across all gestational ages
appeared not to affect negatively the mother’s survival.
Taken together, our literature review underlines the thera-
peutic complexity of CC in pregnant women since deci-
sions have to take into account the impact upon mother and
fetus. Consistent with this observation, different treatment
approaches were also seen in our case series of pregnancy-
associated SCC.
An overview of treatment options according to the
clinical stage is given in Fig. 2 modified after Hunter
et al. [46, 47]. Prolongation of the pregnancy at an early
stage and thus delaying definite treatment were reported
to be safe [3]. Diagnostic conization, though associated
with a significant risk of hemorrhage, might help to assess
the actual invasion depth after biopsy showing micro-in-
vasive disease [4]. Lymph node involvement can be
assessed by MRI scans, thereby providing the basis for
prolonging pregnancy [22]. Alternatively, laparoscopic
lymphadenectomy has emerged as an effective and more
precise procedure during pregnancy [48]. Neoadjuvant
chemotherapy during gestation might be possible in
selected patient groups, defined by advanced disease or
high-risk carcinomas, allowing for fetal maturation.
However, the choice has to be individually made,
weighing the risk of antenatal toxicity against the delay of
curative treatment. Platinum was shown to be a safe
option during pregnancy [49], especially since platinum
concentrations are extremely low in the fetal unit sug-
gesting placental filtration [50]. The timing of delivery is
a critical point in the management of gestation-associated
CC. In accordance with current guidelines, preterm labor
was tolerated in our cohort to compromise between fetal
maturity and completion of the mothers’ oncological
treatment [51].
Table 3 Obstetric characteristics
Case Gravida/para/abortus Delivery Neonatal outcome Long-term follow-up
GA (wks) Mode Weight (centile) Apgar score pH umbilical artery Status Age (yrs)
1 II/I/0 35 CD 2930 g (82) 7/8/9 7.36 Alive 8.43
2 I/0/0 36 CD 2660 g (61) 9/9/9 7.38 Alive 4.22
3 I/0/0 40 CD 3900 g (82) 5/9/10 7.23 Alive 4.07
4 I/0/0 19 Interruption ND ND ND ND ND
5 II/I/0 35 CD 2525 g (56) 5/6/9 7.38 Alive 1.61
CD cesarean delivery, GA gestational age, wks weeks, yrs years
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Undoubtedly, the most successful strategy against CC in
pregnancy is the participation in preconceptive cancer
screening programs. Most of the patients in our cohort did
not undergo regular gynecological examinations before
getting pregnant. Since the Pap smear is an essential part of
early antenatal care, it allows detecting cervical changes
also in the under-screened population and has the advan-
tage to detect a tumor at an early stage. Accordingly, all
CCs in the non-screened patients of our case series were
diagnosed at FIGO stage I, which is in accordance with
published data [52]. Only two patients of our cohort par-
ticipated regularly in the screening program. They were
diagnosed with suspect Pap smears before getting pregnant
and referred for colposcopy only after the onset of preg-
nancy. Their subsequent diagnosis of malignancy underli-
nes the importance of the histopathological evaluation in
the case of repeated abnormal cytological results. Espe-
cially during pregnancy, colposcopy-directed biopsies
should be preferred since hormone-related cellular changes
may be misidentified in Pap smears [53]. Colposcopy-di-
rected biopsy is a safe and reliable procedure during
pregnancy. Delayed bleeding can occur but is often suc-
cessfully resolved with the application of pressure [54].
Taken together, women with suspect Pap test desiring to
bear a child should postpone their pregnancy until definite
treatment of dysplasia took place. Pregnant women with
suspect Pap smears should be referred to a colposcopic unit
where experienced colposcopists are familiar with the
physiological changes of the uterine cervix during preg-
nancy. Being diagnosed with CC during pregnancy, man-
agement depends on different factors including the stage of
disease, the week of gestation and the woman’s desire to
bear a child. Thus, an individualized treatment plan for
each patient is required.
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Fig. 2 Therapeutic algorithm for cervical carcinoma in pregnancy (after [46, 47]). Scheme for the treatment options in women with gestational
cervical cancer according to the FIGO stage (IR interruption, CD cesarean delivery, RH radical hysterectomy)
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